Red Light Holland Corp. and Kala Bio, Inc. announced that Red Light has engaged Kala Bio?s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. The engagement will deploy Kala Bio?s purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.
Red Light recently announced a definitive arrangement agreement to acquire Filament?s business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010. The engagement of the Kala?s Researgency.ai platform represents a key element of Red Light?s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. By deploying custom purpose-built AI agents trained by Younet engineers in collaboration with Kala and under private cloud LLM infrastructure (supplied by Kala), Red Light intends to accelerate and enhance research planning, scenario simulation, and protocol optimization processes associated with advancing PEX010 through its clinical development program.
PEX010 is Filament?s patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others. These indications represent areas of growing clinical and commercial momentum, with programs from Compass Pathways and AtaiBeckley also advancing psilocybin and psychedelic candidates toward late-stage regulatory milestones, and Johnson & Johnson?s Spravato continuing to demonstrate commercial traction in treatment-resistant depression.
The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder.
